Explore

Trendline Trendline
Argenx Acquires Forte Biosciences for $2.2 Billion to Enhance Immunology Portfolio

Argenx Acquires Forte Biosciences for $2.2 Billion to Enhance Immunology Portfolio

Argenx Acquires Forte Biosciences for $2.2 Billion to Enhance Immunology Portfolio
Trendline Trendline
Yarrow Bioscience Completes Merger with VYNE Therapeutics, Advances Treatment for Thyroid Diseases

Yarrow Bioscience Completes Merger with VYNE Therapeutics, Advances Treatment for Thyroid Diseases

Yarrow Bioscience Completes Merger with VYNE Therapeutics, Advances Treatment for Thyroid Diseases
Trendline Trendline
Processa Pharmaceuticals Acquires Vidya Therapeutics and Secures $200 Million Funding

Processa Pharmaceuticals Acquires Vidya Therapeutics and Secures $200 Million Funding

Processa Pharmaceuticals Acquires Vidya Therapeutics and Secures $200 Million Funding
Trendline Trendline
Taco Group Holdings to Be Acquired by Pentair for $1.4 Billion

Taco Group Holdings to Be Acquired by Pentair for $1.4 Billion

Taco Group Holdings to Be Acquired by Pentair for $1.4 Billion
Trendline Trendline
Mapfre's Acquisition of Safety Insurance Group for $1.54 Billion Seen as Strategically Compelling

Mapfre's Acquisition of Safety Insurance Group for $1.54 Billion Seen as Strategically Compelling

Mapfre's Acquisition of Safety Insurance Group for $1.54 Billion Seen as Strategically Compelling
Trendline Trendline
AbbVie Gains EU Approval for RINVOQ in Treating Non-Segmental Vitiligo

AbbVie Gains EU Approval for RINVOQ in Treating Non-Segmental Vitiligo

AbbVie Gains EU Approval for RINVOQ in Treating Non-Segmental Vitiligo
Trendline Trendline
Doctronic Acquires Summer Health to Enhance Pediatric Care with AI Integration

Doctronic Acquires Summer Health to Enhance Pediatric Care with AI Integration

Doctronic Acquires Summer Health to Enhance Pediatric Care with AI Integration
Trendline Trendline
Argenx Acquires Forte Biosciences for $2.2 Billion to Expand Immunology Portfolio

Argenx Acquires Forte Biosciences for $2.2 Billion to Expand Immunology Portfolio

Argenx Acquires Forte Biosciences for $2.2 Billion to Expand Immunology Portfolio
Trendline Trendline
Argenx Acquires Forte Biosciences to Enhance Autoimmune Disease Portfolio

Argenx Acquires Forte Biosciences to Enhance Autoimmune Disease Portfolio

Argenx Acquires Forte Biosciences to Enhance Autoimmune Disease Portfolio
Trendline Trendline
Argenx Acquires Forte Biosciences for $2.2 Billion to Expand Immunology Pipeline

Argenx Acquires Forte Biosciences for $2.2 Billion to Expand Immunology Pipeline

Argenx Acquires Forte Biosciences for $2.2 Billion to Expand Immunology Pipeline
Trendline Trendline
Yarrow Bioscience Completes Merger with VYNE Therapeutics and Begins Phase 2a/2b Trial for Graves' Disease Treatment

Yarrow Bioscience Completes Merger with VYNE Therapeutics and Begins Phase 2a/2b Trial for Graves' Disease Treatment

Yarrow Bioscience Completes Merger with VYNE Therapeutics and Begins Phase 2a/2b Trial for Graves' Disease Treatment
Trendline Trendline
Oak Hill Bio and RACC Announce Merger to Advance Rare Disease Treatments

Oak Hill Bio and RACC Announce Merger to Advance Rare Disease Treatments

Oak Hill Bio and RACC Announce Merger to Advance Rare Disease Treatments